GENinCode (LON:GENI) Hits New 52-Week Low – Should You Sell?

GENinCode Plc (LON:GENI) reached a new 52-week low on Wednesday . The stock traded as low as GBX 0.80 and last traded at GBX 0.95, with a volume of 14639052 shares traded. The stock had previously closed at GBX 0.88.

GENinCode Stock Up 8.1%

The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.89 and a current ratio of 0.93. The company has a market cap of £6.86 million, a PE ratio of -0.40 and a beta of 0.59. The firm has a fifty day simple moving average of GBX 1.11 and a 200 day simple moving average of GBX 1.49.

GENinCode (LON:GENI) last announced its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) earnings per share for the quarter. GENinCode had a negative return on equity of 409.40% and a negative net margin of 185.47%.The company had revenue of GBX 308 million for the quarter. Equities research analysts predict that GENinCode Plc will post -7.1299999 EPS for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.